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Abstract
Background: The prognostic value of aberrant DNA methylation of cell-free circulating DNA in plasma has not
previously been evaluated in diffuse large B cell lymphoma (DLBCL). The aim of this study was to investigate if
aberrant promoter DNA methylation can be detected in plasma from DLBCL patients and to evaluate this as a
prognostic marker. Furthermore, we wanted to follow possible changes in methylation levels during treatment.
Seventy-four patients were enrolled in the study, of which 59 received rituximab and CHOP-like chemotherapy.
Plasma samples were collected from all patients at the time of diagnosis and from 14 healthy individuals used as
controls. In addition, plasma samples were collected during and after treatment for surviving patients. In total, 158
plasma samples were analyzed for DNA methylation in the promoter regions of DAPK (DAPK1), DBC1, MIR34A, and
MIR34B/C using pyrosequencing.
Results: Aberrant methylation levels at the time of diagnosis were detected in 19, 16, 8, and 10 % of the DLBCL
plasma samples for DAPK1, DBC1, MIR34A, and MIR34B/C, respectively. DAPK1 methylation levels were significantly
correlated with DBC1 and MIR34B/C methylation levels (P < 0.001). For the entire cohort, 5-year overall survival (OS)
rates were significantly lower in the groups carrying aberrant DAPK1 (P = 0.004) and DBC1 (P = 0.044) methylation,
respectively. DAPK1 methylation status were significantly correlated with stage (P = 0.015), as all patients with
aberrant DAPK1 methylation were stages III and IV. Multivariate analysis identified DAPK1 as an independent
prognostic factor for OS with a hazard ratio of 8.9 (95 % CI 2.7–29.3, P < 0.0007). Patients with DAPK1 methylated
cell-free circulating DNA at time of diagnosis, who became long-term survivors, lost the aberrant methylation after
treatment initiation. Conversely, patients that maintained or regained aberrant DAPK1 methylation died soon
thereafter.
Conclusions: Aberrant promoter methylation of cell-free circulating DNA can be detected in plasma from DLBCL
patients and hold promise as an easily accessible marker for evaluating response to treatment and for
prognostication. In particular, aberrant DAPK1 methylation in plasma was an independent prognostic marker that
may also be used to assess treatment response.
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Background
Diffuse large B cell lymphoma (DLBCL) is the most preva-
lent subtype of B cell non-Hodgkin lymphoma [1]. The
prognosis is relatively good for patients responding to the
current standard-of-care treatment: rituximab combined
with cyclophosphamide, doxorubicin, vincristine, and
prednisolone (R-CHOP). However, about one third of the
patients, who do not respond or relapse within 5 years
after treatment, have a poor prognosis [2, 3], and for
DLBCL patients in first complete remission (CR), there is
no survival benefit associated with routine imaging [4].
Thus, there is a need for molecular markers that can
rapidly and accurately identify patients who will not re-
spond to the treatment or have an increased risk of re-
lapse, as well as markers to assess treatment response,
and to detect minimal residual disease (MRD) [5].
Methylation of cytosine residues within the CpG
dinucleotide plays important roles in transcriptional
regulation during differentiation of normal human cells,
but aberrant methylation patterns are also involved in
most human cancers [6], including B cell lymphomas
[7]. Recent studies have shown that epigenetic modifiers,
such as EZH2, MLL2, and TET2, are frequently mutated
in DLBCL and associated with altered epigenetic
patterns [8–10]. Interestingly, it has also been shown
that relapsing patients have more intra-tumor DNA
methylation heterogeneity at diagnosis compared to
relapse-free patients [11].
Silencing of tumor suppressor genes in cancer often
involves methylation of their promotor regions, and
the detection of these methylation events in a large
range of different tissues shows great promise as diag-
nostic, prognostic, and predictive markers in various
human cancers [12, 13]. Ideally, DNA methylation
markers should be detectable in readily accessible
body fluids or tissues.
Solid tumors are known to shed cell-free circulating
DNA (cfDNA) into the bloodstream, which can be iso-
lated from plasma or serum. Normal cells, including
leukocytes, also shed cfDNA into the bloodstream; how-
ever, it has been shown that individuals with solid cancers
harbor the same mutations and methylation patterns in
cfDNA from plasma as in their tumor cells [14].
Tumor-derived cfDNA in serum and plasma has been
detected in patients with DLBCL based on next-generation
sequencing (NGS) of tumor-specific recombination of the
immunoglobulin genes [15–17]. It has also recently been
shown that somatic mutations reflecting the genetic
changes of primary tumors can be detected in cfDNA from
DLBCL patients at time of diagnosis [18, 19]. While these
studies prove the usefulness of detecting tumor-derived
cfDNA in DLBCL, much more work is clearly needed be-
fore standardized tests of cfDNA can be applied in routine
clinical settings [5].
In this contribution, we focus on the detection of
tumor-derived cfDNA in plasma, as serum is likely to
contain DNA derived from leukocytes which lyse during
serum processing [20, 21]. Furthermore, we focused on
the detection of DNA methylation in the promoter re-
gions of the tumor suppressor genes DAPK1, DBC1,
MIR34A, and MIR34B/C, which have been shown to be
frequently methylated in DLBCL biopsies [22–25]. In
addition, methylation of DAPK1 has been shown to be
an independent prognostic factor in DLBCL [22, 26], but
none of these markers have been investigated in easily
accessible tissues, such as plasma. We hypothesized that
aberrant promoter DNA methylation can be detected in
plasma from DLBCL patients and have prognostic value.
Furthermore, we hypothesized that aberrant promoter
DNA methylation in plasma may serve as a marker to
assess treatment response.
Methods
Patient samples
This retrospective study examined material from 74
DLBCL patients treated at Rigshospitalet, Denmark, who
had been diagnosed with DLBCL based on standard hist-
ology and immunophenotyping according to the WHO
guidelines. None of the patients were under treatment for
another malignancy at time of inclusion. Peripheral blood
(PB) plasma was collected from all patients at the time of
diagnosis and 14 days after the fourth and last treatment
cycle, respectively, and 3 months after end of treatment
from surviving patients. In addition, PB plasma samples
were collected from 14 healthy blood donors from the
Danish Blood Donor Study [27]. The patients were diag-
nosed from 2003 to 2007 and at least 5 years of clinical
follow-up were available for all patients except three.
DNA extraction and sodium bisulfite conversion
DNA extractions from plasma were performed with the
ROCHE MagNa Pure, using the MagNA Pure LC Total
Nucleic Acid Isolation kit (Roche Diagnostics, Mannheim,
Germany) for all plasma samples from the normal con-
trols, and the patient samples from time of diagnosis and
end of treatment. The QIAsymphony Circulating NA Kit
(48), cus, G (QIAGEN, Hilden, Germany) was used for the
samples collected during treatment. DNA concentrations
were measured using the Qubit flourometer (Thermo-
Fisher Scientific, Waltham, MA, USA). Between 10 and
100 ng, DNA were converted with the EZ DNA Methyla-
tion kit (Zymo Research, Irvine, CA, USA) according to
the manufactures’ instructions.
DNA methylation detection using pyrosequencing
Traditional methylation-independent PCR pyrosequencing
assays [28] were designed to target the promoter regions of
DAPK1, DBC1, MIR34A, and MIR34B/C. The PCR and
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sequencing primers were designed using the PyroMark
Assay Design 2.0 software (QIAGEN). The primer se-
quences and information about the assays can be found in
(Additional file 1: Table S1). PCR cycling was performed on
the Gene PCR System 9700 (Applied Biosystems, Foster
City, CA, USA). The cycling protocol started with 1 cycle
of 95 °C for 15 min, followed by 45 cycles of 95 °C for 20 s,
58 °C (60 °C for the DAPK1 assay) for 20 s, 72 °C for 20 s,
and 1 cycle of 72 °C for 10 min. For the reaction mixtures,
the PyroMark PCR Master Mix (QIAGEN) was used at a
final concentration at 1×, resulting in a final MgCl2 con-
centration of 1.5 mM. Final primer concentrations were
200 nM and 1 μL bisulfite converted DNA was used as
template. Samples were sequenced on the PyroMark Q24
(QIAGEN) using the PyroMark Gold Q24 reagents
(QIAGEN), according to the manufactures’ instructions.
Methylated DNA (Chemicon, Millipore, Billerica, MA),
unmethylated DNA (QIAGEN), and a no template control
(NTC) were included in all experiments. Aberrant methyla-
tion was defined as a methylation level above the mean
methylation level plus two standard deviations of the con-
trol group. The cutoffs were 5.5, 20.9, 4.2, and 7.8 % for
DAPK1, DBC1,MIR34A, andMIR34B/C, respectively.
Statistical analyses
Statistical analyses were performed in SPSS 19.0 for
Windows (SPSS Inc.) and in Prism 6 (GraphPad software,
San Diego, CA, USA). Goodness-of-fit linear regression
was used to evaluate possible relations between methyla-
tion levels and DNA concentrations as well as DAPK1
methylation levels and methylation levels of the other
markers by employing an F test to evaluate if the slopes
were significantly different from zero. Correlations be-
tween 5-year overall survival (OS) rates and methylation
status as well as clinical characteristics were estimated
using the Kaplan-Meier method with the use of a log-rank
test. Hazard ratios (HR) and 95 % confidence intervals
(CI) were calculated using a univariate Cox proportional
hazard model. The clinical characteristics and treatment
outcomes were compared according to DAPK1 methyla-
tion status using Students T tests, Pearson’s chi-square
tests, or Fisher’s exact tests when expected values were
below five. For assessment of independent predictors of
OS, a multivariate Cox regression hazard model was ap-
plied. Any differences were considered to be statistically
significant when the P value was <0.05.
Results
cfDNA concentrations in the plasma samples
The cfDNA concentrations were significantly higher for
the samples collected at time of diagnosis compared to
the normal control samples (P < 0.0001), while there was
no difference between the samples from time of diagno-
sis and the samples collected after treatment (Fig. 1).
Detection of aberrant methylation in the plasma samples
The methylation analyses were successful for all samples
for all markers except MIR34B/C, which failed for 12
and 13 of the diagnostics samples and samples collected
after end of treatment, respectively. For DAPK1 aber-
rantly methylated DNA in plasma was detected in 14
(19 %) of the patients at the time of diagnosis, while only
2 (4 %) were methylated after end of treatment. For
DBC1, MIR34A, and MIR34B/C, aberrantly methylated
DNA were detected in 12 (16 %), 6 (8 %), and 6 (10 %)
of the patients at the time of diagnosis, respectively,
while 6 (13 %), 4 (9 %), and 5 (15 %) were methylated
after end of treatment, respectively (Fig. 2). DAPK1
methylation levels were significantly correlated with
DBC1 and MIR34B/C (P < 0.001 for both), but not with
MIR34A methylation levels (Additional file 2: Figure S1).
None of the markers were correlated with the DNA con-
centration in the samples (Additional file 3: Figure S2).
Survival analyses according to methylation status and
DNA concentrations
The prognostic value of methylated cfDNA levels at time
of diagnosis was evaluated by analyzing OS rates accord-
ing to each of the four markers for all patients with clin-
ical data available (n = 71) and in separate analyses
including only patients receiving rituximab (n = 59).
When analyzing all patients, the 5-year OS rates were
35.7 and 70.0 % in the DAPK1 methylated group and
unmethylated group, respectively. The hazard ratio for
death in the methylated group was 3.08 (95 % CI, 1.37
to 6.93; P = 0.004). The 5-year OS rates were 41.7 and
67.8 % in the DBC1 methylated and unmethylated
Fig. 1 DNA concentrations in the control plasma samples and the
plasma samples taken at time of DLBCL diagnosis and following
treatment
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group, respectively. The hazard ratio for death in the
methylated group was 2.38 (95 % CI, 1.00 to 5.66; P =
0.044). The 5-year OS rates were 83.3 and 60.9 % in the
MIR34A methylated and unmethylated group, respect-
ively. The hazard ratio for death in the methylated group
was 0.40 (95 % CI, 0.05 to 2.93; P = 0.348). The 5-year
OS rates were 50.0 and 67.9 % in the MIR34B/C methyl-
ated and unmethylated group, respectively. The hazard
ratio for death in the methylated group was 1.64 (95 %
CI, 0.48 to 5.60; P = 0.426) (Fig. 3).
Thirty-eight of the patient samples had elevated DNA
concentrations compared to the normal controls (Fig. 1).
When analyzing all patients, the 5-year OS rates were
63.2 and 63.6 % in the group with elevated DNA
concentrations and the group with normal DNA concen-
trations, respectively. The hazard ratio for death in the
group with elevated DNA concentrations was 0.98 (95 %
CI, 0.45 to 2.12; P = 0.963) (Additional file 4: Figure S3).
The 5-year OS rates for patients receiving rituximab
were 41.7 and 70.2 % in the DAPK1 methylated and
unmethylated group, respectively. The hazard ratio for
death in the methylated group was 2.56 (95 % CI, 1.03
to 6.35; P = 0.036), and the 5-year OS rates were 50.0
and 67.3 % in the DBC1 methylated and unmethylated
group, respectively. The hazard ratio for death in the meth-
ylated group was 1.80 (95 % CI, 1.03 to 4.92; P= 0.245)
(Additional file 5: Figure S4).
DAPK1 methylation status according to patient
characteristics
The clinical characteristics of the DLBCL patients as a
function of DAPK1 methylation status are shown in
Table 1. No significant differences in patient demograph-
ics or disease characteristics according to DAPK1
methylation status were observed, with the exception of
stage, as all patients with aberrant DAPK1 methylation
had stage III or IV cancer. This was expected as it has
been shown in solid tumors that patients with an
advanced stage are more likely to have detectable
tumor-derived cfDNA in plasma as compared to patients
with localized disease [29].
Multivariate analysis of survival according to DAPK1
methylation status
For most baseline risk factors, including male sex, age
above 60 years, extranodal involvement, poor performance
Fig. 2 Methylation levels in the plasma samples. The solid lines represent medians. a DAPK1 methylation levels. b DBC1 methylation levels. c MIR34A
methylation levels. d MIR34B/C methylation levels
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score, and high IPI, a trend towards a poor OS was ob-
served as expected. However, this was not statistically sig-
nificant for any of them, possible due to the limited
sample size (Table 2). Therefore, the fact that aberrant
DAPK1 methylation was a highly significant predictor of
overall survival in this cohort of limited size emphasize its
high potential as a prognostic marker in DLBCL. To fur-
ther substantiate our findings, we performed multivariate
analyses of survival according to DAPK1 methylation sta-
tus. All baseline risk factors (gender, age, LDH, extranodal
involvement, performance score, stadium, B symptoms,
and treatment with rituximab) were included in the Cox
proportional hazard model. The model identified methyla-
tion of DAPK1 as an independent prognostic factor for
OS. The HR for DAPK1 methylation was 8.9 (95 % CI
2.7–29.3, P < 0.0007). None of the other baseline risk fac-
tors were significant with the exception of male sex and
poor performance score (Table 3).
Changes in methylation levels during treatment
Methylation levels for each of the markers were com-
pared between the diagnostic sample and the sample
collected 3 months after the end of treatment for each
of the individual surviving patients. All patients with ab-
errant DAPK1 methylation at the time of diagnosis who
were alive after the end of treatment showed a decrease
in methylation levels, and all except two patients had
methylation levels within the normal range after treat-
ment (Fig. 4a). For DBC1, 11 of the patients showed a
greater than 5 % decrease in methylation levels, while 10
of the patients showed a greater than 5 % increase.
Altogether, aberrant methylation was detected in six of
the patients after treatment (Fig. 4b). For MIR34A, one
patient showed a greater than 5 % decrease in the
methylation level, and one patient showed a greater than
5 % increase. Altogether, aberrant methylation was de-
tected in four of the patients after treatment (Fig. 4c).
For MIR34B/C, two patients showed a greater than 5 %
decrease in methylation levels, and one patient showed a
greater than 5 % increase. Altogether, aberrant methyla-
tion was detected in five of the patients after treatment
(Fig. 4d).
None of the patients had a decrease in DAPK1 methy-
lation and an increase in DBC1 methylation and vice
Fig. 3 Overall survival of the entire cohort according to methylation status. a DAPK1. b DBC1. c MIR34A. d MIR34B/C
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versa (Fig. 5), indicating that the aberrant methylation is
tumor-specific.
For 14 of the patients with a DAPK1 and/or DBC1
methylated sample at the time of diagnosis, one or two
samples collected during treatment were available. These
additional samples were tested for DAPK1 and DBC1
methylation (Fig. 6). For all of these patients, except pa-
tient 13, the DAPK1 methylation levels decreased to a
level within the normal range after the treatment was
initiated. Patient 13 relapsed and died 181 days after
diagnosis. Six patients survived at least 5 years following
diagnosis, and all of these retained a DAPK1 methylation
level within the normal range for all samples collected
during and after treatment. One of the patients (patient 4)
died less than a week after the DAPK1 methylation level
increased to an aberrant level, and two patients (patients 1
and 11) died 9 and 12 weeks, respectively, after a slight in-
crease in DAPK1 methylation levels was measured. Two
of the patients (patients 7 and 12) survived for more than
30 weeks following their last DAPK1 methylation mea-
surements, which were within the normal range. The last
Table 1 Clinical characteristics of the DLBCL patients according
to DAPK1 methylation status
Total
(n = 71)
Unmethylated
(n = 57)
Methylated
(n = 14)
P value
Sex 0.136
Men 38 33 5
Women 33 24 9
Extranodal
involvement
0.098
Yes 53 40 13
No 18 17 1
Stage 0.015
I–II 18 18 0
III–IV 53 39 14
Elevated LDHb 1.000
Yes 51 40 11
No 17 14 3
B symptomsb 1.000
Yes 20 16 4
No 49 39 10
IPI scoreb 0.404
0–2 26 22 4
3–5 42 32 10
Performance
scorea
1.000
0–2 62 50 12
3–4 9 7 2
Responseb 0.367
CR 51 43 8
PD/PR 10 7 3
Mors 4 2 2
Age at diagnosis
(grouped)
0.959
<60 years 30 24 6
≥60 years 41 33 8
Age at diagnosis 0.653
Age, mean
(range)
60 years
(23–85)
60 years
(23–85)
59 years
(35–72)
Rituximabb 1.000
Yes 59 47 12
No 11 9 2
LDH lactate dehydrogenase, IPI international prognostic index, CR complete
response, PD progressive disease, PR partial response
aEastern Cooperative Oncology Group
bData was not available for all patients
Table 2 Impact of clinicopathological parameters on OS in DLBCL
Total (n = 71) Number of events P value
Sex 0.219
Men
Women
38
33
16
10
Extranodal involvement 0.068
Yes
No
53
18
23
3
Stage 0.520
I–II
III–IV
18
53
8
18
Elevated LDHb 0.210
Yes
No
51
17
16
8
B symptomsb 0.149
Yes
No
20
49
10
15
IPI scoreb 0.431
0–2
3–5
26
42
8
16
Performance scorea 0.114
0–2
3–4
62
9
21
5
Responseb 0.061
CR
PD/PR
51
10
14
5
Age at diagnosis 0.059
<60 years
≥60 years
30
41
7
19
Rituximabb 0.782
Yes
No
59
11
21
4
LDH lactate dehydrogenase, IPI international prognostic index, CR complete
response, PD progressive disease, PR partial response
aEastern Cooperative Oncology Group
bData was not available for all patients
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patient (patient 9) died from the disease 11 weeks after
the final DAPK1 methylation measurement, which was
within the normal range. For several of the surviving pa-
tients DBC1 methylation levels increased more than
DAPK1 methylation levels, and one patient (patient 10)
increased to an aberrant level, but survived more than
5 years following diagnosis.
Altogether, these analyses demonstrate that DAPK1
methylation in cfDNA from plasma has a potential as a
marker to assess treatment response in DLBCL.
Discussion
The possibility to assess tumor-specific molecular char-
acteristics simply by analyzing peripheral blood, without
the need for an invasive tumor biopsy, has been an ob-
jective in molecular diagnostics for long. A breakthrough
in this area came with the discovery of tumor-specific
cfDNA and circulating tumor cells in plasma and serum,
which led to the concept known as “liquid biopsy” [30].
Different strategies have been employed for the detec-
tion of tumor-specific cfDNA in DLBCL [16, 17, 19, 31].
Frickhofen et al. detected rearrangements of the IgH
locus in plasma and serum as a marker of tumor-specific
cfDNA and showed that the presence of tumor-specific
DNA may be used for monitoring response to treatment
in B cell malignancies [17]. However, patients with a
negative test result later relapsed, and the specificity of
this approach as a response marker is not clear. He et al.
Table 3 Multivariate Cox regression analyses for baseline risk factors in DLBCL
Baseline risk factor Hazard
ratio
95 % hazard ratio confidence limits P
valueLower Upper
Age above 60 years 2.85 0.97 8.41 0.058
Male sex 4.10 1.41 11.92 0.010
Poor performance 5.36 1.56 18.41 0.008
Stage (III–IV) 0.44 0.13 1.42 0.169
Extranodal involvement 1.32 0.34 5.07 0.687
B symptoms 1.80 0.68 4.80 0.238
Not treated with rituximab 0.55 0.15 2.10 0.383
Elevated LDH 0.73 0.26 2.06 0.553
DAPK1 methylation 8.93 2.72 29.31 0.0007
Fig. 4 Methylation levels before and after treatment for surviving patients. Each solid line represents a sample pair. The dashed lines represent the
individual cutoffs for aberrant methylation. a DAPK1. b DBC1. c MIR34A. d MIR34B/C
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later refined this approach by using NGS followed by
PCR to detect specific rearranged IgH DNA fragments
in plasma [16], but the usefulness of this approach as a
prognostic marker or as a marker of MRD following
therapy was not evaluated. In a preliminary study, Hosny
et al. detected TP53 mutations in plasma using direct
Sanger sequencing and a PCR-restriction digestion
analysis, but no comparisons to clinical outcome were
performed [19]. Bohers et al. recently detected tumor-
specific cfDNA in plasma by sequencing a panel of 34
genes recurrently mutated in lymphoma using Ion Tor-
rent (Life Technologies) NGS. Their study showed that
the mean variant allele frequency can be expected to be
lower in cfDNA compared to primary tumor biopsies,
and not all mutations present in the tumor samples may
be detected in plasma samples [18]. Finally, Jones et al.
detected circulating Epstein-Barr virus (EBV) DNA in
plasma and serum as a marker of tumor-specific cfDNA,
and showed that the presence of tumor-specific DNA
correlated with clinical/radiological response. However,
this approach is only applicable to EBV-associated
lymphoma [31], and it is unclear if the presence of EBV
DNA in plasma and/or serum at the time of diagnosis
has prognostic value.
We adopted a different approach for the detection of
tumor specific cfDNA in DLBCL, namely the detection
of aberrant DNA methylation by pyrosequencing. This
method is currently in use in clinical settings for the de-
tection of O6-methylguanine-DNA methyltransferase
(MGMT) methylation, which is used as a prognostic and
predictive biomarker in glioblastoma treated with alkyl-
ating agents [32–34].
As a proof of principle, we selected four tumor suppres-
sor genes, DAPK1, DBC1,MIR34A, andMIR34B/C, which
have been shown to be frequently methylated in DLBCL
[22–25], and investigated if aberrant methylation levels of
these markers could be detected in plasma from patients
with DLBCL. Aberrant methylation levels were detected
for all markers. However, the frequencies of patients with
aberrant methylation were lower than what have previ-
ously been observed in DLBCL biopsies [22, 24, 25]. This
was expected as cfDNA in plasma contains a larger back-
ground of DNA from normal cells in most cases as com-
pared to tumor biopsies. Furthermore, it has also been
shown for other malignancies that patients harboring solid
tumors with advanced disease are more likely to have de-
tectable tumor-derived cfDNA in plasma as compared to
patients with localized disease [29]. In line with this, we
observed that the presence of aberrant DAPK1 methyla-
tion only occurred for patients with stage III and IV
disease.
cfDNA concentrations were elevated at presentation,
however, a high DNA concentration did not confer a poor
prognosis, and none of the methylation markers we studied
were correlated with DNA concentration. This was ex-
pected as it has previously been shown that tumor-derived
cfDNA, but not non-specific cfDNA, reflects therapeutic
response [31], and it has been shown that samples from
Fig. 5 Correlation between changes in DAPK1 and DBC1 methylation levels during treatment
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patients with pediatric anaplastic large cell lymphoma with
a high percentage of tumor-derived cfDNA tend to have
low concentrations of cfDNA [35]. On the other hand,
quantification of cfDNA based on qPCR for the β-globin
gene, has been shown to correlate with disease characteris-
tics, such as presence of B symptoms, elevated LDH, and
advanced stage disease as well as a poor prognosis [36].
While the detection of tumor-derived cfDNA has po-
tential as a prognostic marker, we hypothesized that the
detection of markers in cfDNA, which have prognostic
value when detected in primary tumor biopsies, may
strengthen that potential. Methylation of DAPK1 in
tumor biopsies has proven to be an independent prog-
nostic marker in DLBCL [22, 26] and is also methylated
in a large proportion of the patients. Indeed, we found
methylation of the DAPK1 gene to be a strong predictor
of OS and it remained statistically significant when cor-
recting for gender, age, LDH, extranodal involvement,
performance score, stage, B symptoms, and treatment
with rituximab. Compared to DAPK1 methylation in
DLBCL biopsies, a much smaller proportion of the pa-
tients have aberrant methylation in cfDNA from plasma,
possibly because only the more advanced tumors shed
DNA into the circulation. This is very important as it is
of exceptional clinical importance to be able to identify a
relatively small group of patients who are not respond-
ing to current treatment modalities, rather than to iden-
tify a small group of patients doing remarkably well, as
is the case for patients with an unmethylated DLBCL bi-
opsy [22]. Another important finding was that patients
with DAPK1 methylated cfDNA at time of diagnosis, who
became long-term survivors, lost the aberrant methylation
after treatment initiation. Conversely, patients that main-
tained or regained aberrant DAPK1 methylation died soon
thereafter. Thus, based on these data, we suggest that the
small group of patients with aberrant DAPK1 methylation
in plasma at the time of diagnosis should be monitored
for DAPK1 methylation during treatment and could
Fig. 6 Methylation levels during treatment. Each plot shows the DAPK1 (green lines) and DBC1 (orange lines) methylation data acquired during treatment for
an individual patient. Time of diagnosis is at week 0 and the treatment was initiated at the same time or 1–2 weeks after the first methylation measurement
(start of solid lines). The last methylation measurement is indicated by the end of the solid lines. Time of death is indicated by a cross. Patients without a cross
survived at least 5 years following their diagnosis. Patient 1 progressed to DLBCL from a follicular lymphoma. Response evaluations are displayed for each
patient. CR complete response, PD progressive disease, N.D. no data
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potentially be selected for relapse treatment if the methy-
lation level increases. A number of new agents have
shown promising results for the treatment of relapsed/re-
fractory DLBCL used as single-agent or in combination
with rituximab-based chemotherapy [37].
At this time, it is unknown if DAPK1 methylation has
functional importance for the resistant/relapsing clones.
If this is the case, it is tempting to speculate whether
DNA methyltransferase inhibitors should be added to
the salvage therapy in these patients as azacitidine plus
standard chemoimmunotherapy in high-risk patients
with newly diagnosed DLBCL is well tolerated and yield
a high rate of complete remission [38].
Finally, it may be possible in the future to reconstitute
the expression of DAPK1 in patients lacking this import-
ant tumor suppressor as delivery of its constitutive kin-
ase domain via a CD22-specific immunoligand has
shown remarkable in vitro efficacy and selectivity in pre-
clinical testing [39].
Conclusions
Aberrant methylation of cfDNA can be detected in plasma
from DLBCL patients and methylation of DAPK1 has a
strong potential as an independent prognostic marker and
may also be used to assess treatment response. However,
these results need to be confirmed in additional independ-
ent and larger cohorts of DLBCL patients before testing for
DAPK1 methylation of cfDNA should be incorporated into
routine clinical practice. Nevertheless, this study highlights
the potential of liquid biopsies in DLBCL as a prognostic
tool and for monitoring patients during and following
treatment.
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